SCHEMBL157494

SCHEMBL157494

Cc1ccc(S(=O)(=O)OCO[PH](=O)O)cc1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
STAT3 P40763 2/20 0.43
GAA P10253 2/20 0.39
KMT2A Q03164 5/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
F2 P00734 1/20 0.39
PRSS1 P07477 1/20 0.39
PRSS2 P07478 1/20 0.39
PRSS3 P35030 1/20 0.39
CYP2D6 P10635 2/20 0.38
ALDH1A1 P00352 5/20 0.38
CA1 P00915 2/20 0.38
CA2 P00918 2/20 0.38
MMP1 P03956 1/20 0.38
MMP2 P08253 1/20 0.38
MMP9 P14780 1/20 0.38
MMP8 P22894 1/20 0.38
MMP13 P45452 1/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
CYP2C19 P33261 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Butane SCHEMBL1393934 0.95 STAT3 (0.40) STAT3GAAKMT2ASMN1; SMN2F2
SCHEMBL157493 0.86 GAA (0.42) STAT3GAAKMT2ASMN1; SMN2F2
SCHEMBL4960150 0.85 GAA (0.41) STAT3GAAKMT2ASMN1; SMN2F2
SCHEMBL28684540 0.83 PARL (0.40) GAAKMT2ASMN1; SMN2ALDH1A1CA1
SCHEMBL3315459 0.82 GAA (0.52) STAT3GAAKMT2ASMN1; SMN2CYP2D6
Fluoride SCHEMBL31533364 0.80 GAA (0.50) STAT3GAAKMT2ASMN1; SMN2CYP2D6
SCHEMBL3165478 0.79 STAT3 (0.44) STAT3GAAKMT2ACYP2D6ALDH1A1
SCHEMBL9905506 0.78 C5AR1 (0.38) STAT3GAAKMT2ASMN1; SMN2ALDH1A1
SCHEMBL11604749 0.78 GAA (0.48) STAT3GAAKMT2ASMN1; SMN2CYP2D6
SCHEMBL3131297 0.77 GAA (0.46) STAT3GAAKMT2ASMN1; SMN2F2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115894554-A Preparation method of phosphonic acid compound 烟台药物研究所 2023-04-04 CN claimed
US-5733896-A VIRICIDE FOR RETROVIRUS INSTITUTE OF ORGANIC CHEMISTRY AND BIOCHEMISTRY OF THE ACADEMY OF SCIENCES OF THE CZECH REPUBLIC (CZ) 1998-03-31 US claimed
CN-120022913-A Method for using high-stability copper-based catalyst in hydrochlorination of acetylene 中盐吉兰泰氯碱化工有限公司 2025-05-23 CN disclosed
CN-115894554-A Preparation method of phosphonic acid compound 烟台药物研究所 2023-04-04 CN disclosed
CN-115894554-A Preparation method of phosphonic acid compound 烟台药物研究所 2023-04-04 CN disclosed
EP-3020720-B1 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX INC (US) 2018-09-19 EP disclosed
CN-106687467-A Method for preparing high-purity (r)-9-[2-(phosphonomethoxy)propyl]adenine 韩美精密化学株式会社 2017-05-17 CN disclosed
CN-105998039-A Phosphonate ester derivatives and methods of synthesis thereof 奇默里克斯公司 2016-10-12 CN disclosed
CN-102939291-B Phosphonate ester for the toxicity with reduction for the treatment of of viral infections 加利福尼亚大学董事会 2016-09-07 CN disclosed
EP-2611818-B1 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX INC (US) 2016-08-24 EP disclosed
CN-103209985-B Phosphonate derivatives and methods of synthesis thereof 奇默里克斯公司 2016-08-24 CN disclosed
EP-2611818-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF Chimerix, Inc. (US) 2013-07-10 EP disclosed
WO-2013072745-A1 PROCESS FOR THE PREPARATION OF TENOFOVIR LAURUS LABS PRIVATE LIMITED (IN) 2013-05-23 WO disclosed
WO-2012081032-A1 PROCESS FOR THE PREPARATION OF TENOFOVIR APTUIT LAURUS PRIVATE LIMITED (IN) 2012-06-21 WO disclosed
US-20120058976-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof CHIMERIX, INC. (US) 2012-03-08 US disclosed
WO-2012031045-A2 PHOSPHONATE ESTER DERIVATIVES AND METHODS OF SYNTHESIS THEREOF CHIMERIX, INC. (US) 2012-03-08 WO disclosed
EP-2086990-A2 NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS Centre National De La Recherche Scientifique-CNRS (FR) 2009-08-12 EP disclosed
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
WO-2008056264-A2 NOVEL NUCLEOTIDE ANALOGUES AS PERCURSOR MOLECULES FOR ANTIVIRALS CENTRE NATIONAL DE RECHERCHE SCIENTIFIQUE (CNRS) (FR) 2008-05-15 WO disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases POLR2H, NSUN2, POLR2E STAT3 2322/4885GAA 2605/4885KMT2A 1027/4885
US-20120058976-A1 Phosphonate Ester Derivatives and Methods of Synthesis Thereof PHOSPHO1, PIK3CA, PNP STAT3 3774/4885GAA 507/4885KMT2A 2791/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.